Biotherapeutics News and Research

RSS

Scientists find potential new way to improve treatment for Von Willebrand Disease

Scientists have found a potential new way to promote blood clotting that could be used to help develop treatments for Von Willebrand Disease, the most common genetic bleeding disorder.

12 Jun 2020

Avacta provides update on COVID-19 antigen diagnostic test development with Adeptrix

Avacta Group plc is pleased to announce that a BAMS™ diagnostic test for COVID-19, being developed with Adeptrix, has reached the prototype stage.

From Avacta Life Sciences Ltd. 9 Jun 2020

CSL Behring and Seattle Children's partner to develop gene therapies for primary immunodeficiency diseases

Seattle Children's Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL Behring announced a strategic alliance to develop stem cell gene therapies for primary immunodeficiency diseases.

2 Jun 2020

New Thermo Scientific Proteome Discoverer 2.5 software strengthens laboratory workflows

Scientists in the life sciences can now benefit from upgrades to a suite of analytical software solutions with new features designed to enhance productivity, confidence and accuracy in numerous fields, including proteomics, food safety and biotherapeutic drug development.

From Thermo Fisher Scientific Inc. 28 May 2020

New high-resolution mass spectrometer expands the proven Thermo Scientific Orbitrap platform

A new generation, high resolution mass spectrometer (MS) is designed to give proteomics, metabolomics, biopharmaceutical characterization and small-molecule scientists the analytical performance required for research and high-throughput analyses.

From Thermo Fisher Scientific Inc. 28 May 2020

Airway and Celonic collaborate to produce AT-100 as therapeutic candidate against COVID-19

Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, and Celonic Group, a premium biopharmaceutical CDMO specialized in the development and production of Advance Therapy Medicinal Products (ATMPs) and mammalian cell line-expressed biotherapeutics, today announced a collaboration to produce the novel human recombinant protein AT-100 (rhSP-D) as a therapeutic candidate against COVID-19.

21 May 2020

Avacta and Medusa19 enter into a distribution agreement for COVID-19 antigen test

Avacta Group plc has entered into an exclusive distribution agreement with Medusa19 Limited for sales of a saliva-based rapid test for the COVID-19 antigen.

From Avacta Life Sciences Ltd. 20 May 2020

Rentschler Biopharma licenses Horizon Discovery’s CHOSOURCE platform to complement cell line development offering for difficult-to-express proteins

Rentschler Biopharma SE, and Horizon Discovery, a leader in the application of gene editing, today announced the signing of a commercial license agreement.

From Revvity 19 May 2020

Avacta's SARS-COV-2 neutralizing Affimer reagents show therapeutic potential for COVID-19

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that several of the Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between the virus’ spike protein and ACE2, a receptor on human cells that is key to the virus infection pathway.

From Avacta Life Sciences Ltd. 18 May 2020

Avacta Group plc forms COVID-19 antigen diagnostic collaboration with Adeptrix

Avacta Group plc is pleased to announce that it has entered into a collaboration with Adeptrix to develop a high throughput COVID-19 antigen test.

From Avacta Life Sciences Ltd. 1 May 2020

Avacta successfully generates several highly specific Affimer reagents for COVID-19 antigen rapid test ahead of schedule as part of Cytiva partnership

Avacta Group plc is pleased to announce that it has successfully generated multiple Affimer reagents that bind the SARS-COV-2 viral antigen.

From Avacta Life Sciences Ltd. 22 Apr 2020

Accelerating Antibody Discovery with Next-Generation Single-Cell Analysis

Accelerating antibody discovery using picodroplet technology for single cell analysis to condense discovery times down to 1-2 days.

From Sphere Fluidics 22 Apr 2020

Avacta partners with Cytiva to develop a rapid test for COVID-19

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Cytiva, formerly known as GE Healthcare Life Sciences.

From Avacta Life Sciences Ltd. 9 Apr 2020

Wyatt Technology Pioneers Multi-CQA Method for Gene Vectors

Wyatt Technology, the world leader in instrumentation for absolute macromolecular and nanoparticle characterization, announces the release of a novel method suitable for determining multiple critical quality attributes of adeno-associated virus and similar small gene vectors, in a single chromatographic run.

From Waters | Wyatt Technology 8 Apr 2020

Isolating Single T-cells of Interest using an Optofluidic Platform

Researchers are in desperate need of single-cell analysis techniques and those that allow the isolation of high-value T-cells for research and development.

From Bruker Cellular Analysis 21 Feb 2020

Avacta demonstrates initial proof-of-concept for TMAC drug conjugates in pre-clinical study

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it has demonstrated initial proof-of-concept for its proprietary new class of drug conjugate, TMAC, in a pre-clinical animal model of cancer.

From Avacta Life Sciences Ltd. 28 Jan 2020

GlobalData: China can use the lessons learnt from SARS epidemic to control Wuhan coronavirus

Following the news that cases of people infected with the Wuhan coronavirus rose to more than 270 laboratory-confirmed cases and the virus may spread from human-to-human.

22 Jan 2020

Horizon Discovery enters into licensing agreement with NGM for GS knockout CHO K1 cell line

Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that it will license its gene-edited Glutamine Synthetase knockout Chinese Hamster Ovary K1 cell line to NGM Biopharmaceuticals, Inc..

From Revvity 22 Jan 2020

Turbine appoints new SAB members to guide its simulation-first drug discovery mission

Turbine, a simulation-first drug discovery company, today announced the formation of its Scientific Advisory Board with the appointments of Dr. Annalisa Jenkins, Dr. Mihriban Tuna, and Dr. Alan Barge.

21 Jan 2020

Avacta and Daewoong Pharmaceutical announce joint venture to develop novel cell and gene therapies

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, and Daewoong Pharmaceutical Co. Ltd., a leading Korean pharmaceutical company, are pleased to announce that they have agreed to establish a joint venture in South Korea, and to enter a collaboration and license agreement for the joint venture to develop the next generation of cell and gene therapies incorporating Affimer proteins to enhance the immune-modulatory effects.

From Avacta Life Sciences Ltd. 9 Jan 2020